MeltDose® Technology Platform

MeltDose®, the Veloxis proprietary technology platform for enhancing the bioavailability of compounds with low water solubility, allows Veloxis to create novel versions of marketed drugs. This technology has been validated in clinical studies and has received regulatory acceptance through the FDA for approval of Fenoglide® for sale in the US.

Independent studies have shown that approximately 30% of existing drugs have suboptimal uptake and absorption due to low water solubility (source: Technology Catalysts International; Delivery of Poorly Soluble or Poorly Permeable Drugs, 4 ed.). Veloxis believes that a large number of these drugs may be suitable candidates for the company's proprietary MeltDose® technology. MeltDose® may also be of value for new chemical entities (NCEs) for which low absorption of a particular drug presents a significant barrier to its final formulation and ultimately to its development as an actual drug.

The fundamental limiting factor for oral absorption of drugs with low water solubility is the transfer of drug substance particles to dissolved molecules that can penetrate the epithelium (a group of cells) of the gastrointestinal tract and enter into the bloodstream. The majority of conventional drug delivery technologies aimed at increasing bioavailability of compounds with low water solubility rely on reduction of the particle size of the drug substance, thereby increasing the surface area available for the dissolution process.